High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4127-4130

  Chadha, Manpreet K ^a   Lombardo, Jeffrey ^a   Mashtare, Terry ^a   Wilding, Gregory E ^a   Litwin, Alan ^a   Raczyk, Cheryl ^a   Gibbs, John F ^a   Kuvshinoff, Boris ^a   Javle, Milind M ^b   Iyer, Renuka V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Neuroendocrine tumors; Octreotide

Indexed keywords

ALPHA INTERFERON; OCTREOTIDE;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; RETROSPECTIVE STUDIES;

EID: 71949124721     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Capella C, Heitz PU, H fler H, Solcia E and Kloppel G: Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch (A) 425: 547-560, 1995.
2. Madeira I, Terris B, Voss M et al: Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43: 422-427, 1998. (Pubitemid 28414926)
3. Mignon M, Ruszniewski P, Haffar S, Rigaud D, Ren E and Bonfils S: Current approach to the management of tumoral process in patients with gastrinoma. World J Surg 10: 703-710, 1986. (Pubitemid 16096430)
4. Godwin D: Carcinoid tumors; an analysis of 2837 cases. Cancer 45: 104-110, 1980.
5. Zeitels J, Naunheim K, Kaplan EL and Strauss F: Carcinoid tumors: a 37-year experience. Arch Surg 117: 732-737, 1982.
6. Moertel CG: An Odyssey in the land of small tumors. J Clin Oncol 5: 1503-1522, 1987.
7. Moertel CG, Lefkopoulos M and Lipsitz M: Streptozocin-doxorubicin, Streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519-523, 1992.
8. Moertel CG, Kvols LK, O'Connell MJ and Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Cancer 68: 227-232, 1991.
9. Kvols LK, Moertel CG, O'Connell MJ et al: Treatment of the malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue. N Engl J Med 315: 663-666, 1986. (Pubitemid 16055931)
10. Oberg K, Norheim I, Lind E et al: Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep 70: 1297-1304, 1986. (Pubitemid 17184294)
11. Ruszniewski P, Rougier P, Roche A et al: Hepatic arterial chemoembolization in patients with liver metastases of neuroendocrine tumors. A prospective phase II study in 24 patients. Cancer 71: 2624-2630, 1993.
12. Ruszniewski P, Ducreux M, Chayvialle JA et al: Treatment of the carcinoid syndrome with long acting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut 39: 279-283, 1996. (Pubitemid 26276007)
13. Davis Z, Moertel CG and McIlrath DC: The malignant carcinoid syndrome. Surg Gynecol Obstet 137: 628-644, 1973.
14. Reubi JC, Schaer JC, Waser B and Mengod G: Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54: 3455-3459, 1994.
15. Arnold R, Simon B and Wied M: Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 62(Suppl 1): 84-91, 2000. (Pubitemid 30665945)
16. Arnold R, Trautmann ME, Creutzfeldt W et al: the German Sandostatin Multicentre Study Group: Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 38: 430-438, 1996.
17. Saltz L, Trochanowski B, Buckley M et al: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 72: 244-248, 1993. (Pubitemid 23182080)
18. Eriksson B, Renstrup J, Iman H and Oberg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumor: clinical and biological effects. Ann Oncol 8: 1041-1044, 1997. (Pubitemid 27475737)
19. Arnold R, Müller H, Schade-Brittinger C, Rinke A, Klose K, Barth P, Wied M, Mayer C, Aminossadati B, PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. Gastrointestinal Cancer Symposium, Abstract 121, 2009.
20. Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E et al: Induction of apoptosis in neuroendocrine tumours of the digestive system during treatment with somatostatin analogues. Acta Oncologica 36: 607-614, 1997. (Pubitemid 27512573)
21. Anthony L, Johnson D, Hande K, Shaff M,Winn S, Krozely M et al: Somatostatin analogue phase 1 trials in neuroendocrine neoplasms. Acta Oncologica 32: 217-223, 1993. (Pubitemid 23188539)
22. Eriksson B, Renstrup J, Imam H and O'berg K: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumours: clinical and biological effects. Ann Oncol 5: 1041-1044, 1997. (Pubitemid 27475737)
23. Welin SV, Janson ET, Sundin A, Stridsberg M, Lavenius E, Granberg D, Skogseid B, Oberg KE and Eriksson BK: High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol 151(1): 107-112, 2004. (Pubitemid 39117371)